Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-MS
2023-510228-63-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Apr 2024
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of mesenchymal stem cells in primary progressive multiple sclerosis (PPMS) and secondary-progressive multiple sclerosis (SPMS) (2 arms), sponsored by Helse Bergen. Primary endpoint: Difference in combined evoked potentials at 6 months. Planned start Apr 2024; status: authorised.
02
Drugs
mesenchymal stem cells
03
Conditions
primary progressive multiple sclerosis (PPMS)secondary-progressive multiple sclerosis (SPMS)
Beyond the preview
Go deeper on 2023-510228-63-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510228-63-00.